Answers are grounded in this paper and cite their sources.
We conclude that enhanced STAT5A or STAT5B action both drive PTCL development, defining both STAT5 molecules as targets for therapeutic intervention.
No takes yet. Share an insight, caveat, or question.
Maurer et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: